Word

INGENOX

Status

Pending

Status Code

681

Status Date

Thursday, March 14, 2024

Serial Number

98015655

Mark Type

3000

Filing Date

Friday, May 26, 2023

Published for Opposition

Tuesday, April 23, 2024

Trademark Owner History

INGENOX THERAPEUTICS LIMITED

Classifications

5 Epigenetic drugs for the treatment, diagnosis, detection and/or prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; inhibitors of arginine methylation for the treatment of cancer; inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; compounds for the treatment, diagnosis, detection and/or prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer

42 biochemical research and development services; medical research and development services; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and/or cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; consultancy, advisory and/or information services relating to or connected with the aforementioned services

The mark consists of letters spelling ingenOx horizontally with all letters in lower case except for O which is capitalized. The letter g is in a stylized font. There is a molecule shape after letter x.
Color is not claimed as a feature of the mark.

Trademark Events

Apr 3, 2024

Notification Of Notice Of Publication E-Mailed

Mar 13, 2024

Approved For Pub - Principal Register

Mar 13, 2024

Examiner's Amendment Entered

Mar 13, 2024

Notification Of Examiners Amendment E-Mailed

Mar 13, 2024

Examiners Amendment E-Mailed

Mar 13, 2024

Examiners Amendment -Written

Mar 11, 2024

Previous Allowance Count Withdrawn

Mar 5, 2024

Withdrawn From Pub - Og Review Query

Feb 20, 2024

Approved For Pub - Principal Register

Feb 20, 2024

Assigned To Examiner

Jun 29, 2023

Notice Of Design Search Code E-Mailed

Jun 28, 2023

New Application Office Supplied Data Entered

May 30, 2023

New Application Entered